Veliparib is an investigational oral PARP inhibitor used in combination with chemotherapy or radiation to prevent cancer cells from repairing DNA damage. It is mainly studied for the treatment of solid tumors, including breast, ovarian, and lung cancers, especially in patients with BRCA1/2 mutations. It is grouped under the following drug class(es): PARP Inhibitors. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Veliparibum, Benzimidazole carboxamide and 3a. Its PubChem CID is 11960529.
Veliparib
| CAS No | 912444-00-9 |
|---|---|
| Molecular Formula | C13H16N4O |
| Molecular Weight | 244.29 g/mol |
| Synonyms | 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Veliparib is an investigational oral PARP inhibitor used in combination with chemotherapy or radiation to prevent cancer cells from repairing DNA damage. It is mainly studied for the treatment of solid tumors, including breast, ovarian, and lung cancers, especially in patients with BRCA1/2 mutations.
The listed CAS number is 912444-00-9.
The listed molecular formula is C13H16N4O.
The listed molecular weight is 244.29 g/mol.
2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide.
The source lists Veliparibum, Benzimidazole carboxamide and 3a.